Auer, Michael http://orcid.org/0000-0002-5117-4225
Bauer, Angelika
Oftring, Antonia
Rudzki, Dagmar
Hegen, Harald
Bsteh, Gabriel
Di Pauli, Franziska
Berek, Klaus
Zinganell, Anne
Berger, Thomas
Reindl, Markus
Deisenhammer, Florian
Article History
Accepted: 31 August 2022
First Online: 29 September 2022
Declarations
:
: There was no funding for this research.
: Michael Auer received speaker honoraria and/or travel grants from Biogen, Merck, Novartis, and Sanofi Genzyme. Angelika Bauer, Antonia Oftring, and Dagmar Rudzki report no conflicts of interest. Harald Hegen has participated in meetings sponsored by and has received speaker honoraria or travel funding from Bayer, Biogen, Celgene, Merck, Novartis, Sanofi-Genzyme, Siemens, and Teva, and received honoraria for consulting from Biogen, Celgene, Novartis, and Teva. Gabriel Bsteh has participated in meetings sponsored by and received speaker honoraria or travel funding from Biogen, Celgene/BMS, Lilly, Merck, Novartis, Roche, Sanofi-Genzyme, and Teva, and received honoraria for consulting Biogen, Celgene/BMS, Novartis, Roche, Sanofi-Genzyme, and Teva. He has received unrestricted research grants from Celgene/BMS and Novartis. Franziska Di Pauli has participated in meetings sponsored by and received honoraria (lectures, advisory boards, consultations) or travel funding from Bayer, Biogen, Merck, Novartis, Sanofi-Genzyme, Teva, Celgene, and Roche. Klaus Berek has participated in meetings sponsored by and received travel funding from Roche, Biogen, and Teva. Anne Zinganell has participated in meetings sponsored by and received speaking honoraria or travel funding from Biogen, Merck, Sanofi-Genzyme, and Teva. Thomas Berger has participated in meetings sponsored by and received honoraria (lectures, advisory boards, consultations) from pharmaceutical companies marketing treatments for MS: Allergan, Bayer, Biogen, Bionorica, Celgene, MedDay, Merck, Novartis, Octapharma, Roche, Sanofi-Genzyme, and Teva. His institution has received financial support in the past 12 months by unrestricted research grants (Biogen, Bayer, Merck, Novartis, Sanofi Aventis, and Teva and for participation in clinical trials in MS sponsored by Alexion, Bayer, Biogen, Merck, Novartis, Octapharma, Roche, Sanofi-Genzyme, and Teva). Markus Reindl reports no conflicts of interest relating to the present article. Florian Deisenhammer has participated in meetings sponsored by or received honoraria for acting as an advisor/speaker for Alexion, Almirall, Biogen, Celgene, Merck, Novartis, Roche, and Sanofi-Genzyme. His institution received scientific grants from Biogen and Sanofi-Genzyme.
: The study was approved by the Ethics Committee of the Medical University of Innsbruck, Austria (approval number 1341/2020).
: For storage of samples, patients had to sign a written informed consent for the use of excess material for scientific purposes at the time of sampling.
: Not applicable.
: Not applicable.
: Data are available upon reasonable request from the corresponding author.
: MA: study concept and design, patient recruitment, acquisition and interpretation of data, statistical analysis, drafting of manuscript. AB: performance of assays, acquisition of data, critical revision of manuscript for intellectual content. AO: performance of assays, acquisition and interpretation of data, critical revision of manuscript for intellectual content. DR: performance of assays, acquisition of data, critical revision of manuscript for intellectual content. HH: patient recruitment, acquisition of data, critical revision of manuscript for intellectual content. GB: patient recruitment, acquisition of data, critical revision of manuscript for intellectual content. FDP: patient recruitment, acquisition of data, critical revision of manuscript for intellectual content. KB: patient recruitment, acquisition of data, critical revision of manuscript for intellectual content. AZ: patient recruitment, acquisition of data, critical revision of manuscript for intellectual content. TB: patient recruitment, acquisition of data, critical revision of manuscript for intellectual content. MR: performance of assays, acquisition of data, critical revision of manuscript for intellectual content. FD: study concept and design, patient recruitment, acquisition of data, interpretation of data, critical revision of manuscript for intellectual content, supervision. All authors have read and approve the final submitted version of the manuscript and agree to be accountable for the work.